Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Using midodrine to accelerate weaning of intravenous vasopressors in acute spinal cord injured patients admitted to the intensive care unit: A retrospective study of 28 patients.

Created on 10 Sep 2025

Authors

Vivian Huong Hoang Thien Le, Pascal Mputu Mputu, Andréane Richard-Denis, Francis Bernard, Yiorgos Alexandros Cavayas, Jean-Marc Mac-Thiong

Published in

The journal of spinal cord medicine. Pages 1-8. Sep 09, 2025. Epub Sep 09, 2025.

Abstract

A retrospective study with a crossover design.
Maintaining mean arterial pressure (MAP) is crucial in the early management of SCI, yet the role of oral midodrine in this setting remains unclear. This study evaluates whether midodrine facilitates IV vasopressor weaning within 24 hours of initiation.
The study was conducted at a Level 1 trauma center.
A cohort of 28 patients was analyzed. MAP levels and IV vasopressor dosages were recorded 24 hours before and after midodrine initiation. The primary outcome was reduced IV vasopressor use while maintaining MAP targets.
Midodrine was started on average 4.0±1.9 days after initiation of intravenous vasopressor therapy. Twenty-two individuals (78.6%) received less intravenous vasopressors during the 24-hour period after initiation of midodrine. Mean MAP remained similar 24 hours before vs. after initiation of midodrine (90.4±3.3 vs. 88.6±5.1 mm Hg). Earlier introduction of midodrine was significantly related to more rapid weaning and reduced total duration of intravenous vasopressor therapy.
Initiating oral midodrine in the ICU within 7 days of a traumatic SCI resulted in a rapid decrease in intravenous vasopressor requirements in close to 80% of people while maintaining MAP targets, therefore supporting the potential of midodrine to accelerate the weaning of intravenous vasopressors.

PMID:
40924897
Bibliographic data and abstract were imported from PubMed on 10 Sep 2025.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 65
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement